International journal of colorectal disease
-
Int J Colorectal Dis · May 2012
Meta AnalysisMeta-analysis of the association between progression-free survival and overall survival in metastatic colorectal cancer.
The validity of progression-free survival (PFS) as a surrogate endpoint for overall survival (OS) in metastatic colorectal cancer (mCRC) trials has been studied, primarily in first-line treatment. The relationship between PFS and OS has not been well studied in later lines of treatment. ⋯ The correlation of PFS, alone or aggregated with TTP, with OS in clinical trials of patients with mCRC is robust across lines of therapy and provides a useful means of predicting improvements in OS using PFS data.